This report provides a regulatory update on a Lipiodol based embolization trial for chronic plantar fasciitis and explains who should watch the study status.
Publication date context: 2026-02-19
In this article
- What is the trial about?
- What device and method are used?
- What is the trial status and regulatory context?
- What are implications for clinicians?
- FAQ
What is the trial about?
The ClinicalTrials.gov listing describes a study focused on chronic plantar fasciitis. The intervention is described as Lipiodol, used for embolization of the lateral plantar artery. The sponsor is Joint & Vascular Institute, and the study is currently recruiting. The public record does not provide efficacy results at this time. The study record identifies a regulatory framework under which the trial operates and signals ongoing participant enrollment, underscoring the early stage nature of the investigation.
The listing illustrates an approach that is being explored within a vascular intervention context. It highlights the intent to evaluate a procedure that targets a specific arterial supply in the region associated with plantar fasciitis symptoms. As a public records item, it serves as a notice to the medical community about potential future options and the need for careful monitoring of safety and performance signals as the trial progresses.
What device and method are used?
Device and procedure details
The record lists Lipiodol as the device used in the intervention. The public listing does not disclose procedural steps or outcome data in detail. Because the document provides limited technical information, clinicians and researchers should rely on the official trial registry for updates and any subsequent publications that describe methodology, patient selection criteria, and safety monitoring plans if they become available. The absence of disclosed procedural specifics means no independent replication can be inferred from the listing alone.
There is no claim of comparable effectiveness or direct comparative data within the listing. Regulatory observers will watch how the sponsor documents vital signs, adverse events, and other safety indicators as the trial advances. The listing also does not provide information about imaging guidance, anesthesia, or postprocedural care that might accompany an embolization based intervention. Users should treat the listing as a preliminary notice rather than a complete protocol description.
What is the trial status and regulatory notes?
The listing notes recruiting status. The sponsor is identified as Joint & Vascular Institute. This is a clinical trial listing and does not imply regulatory approval for marketing or use outside a trial context. The link provided points to ClinicalTrials.gov for official status and updates. For additional context see Plantar Fasciitis Regulatory Update and Vasculature Embolization Techniques.
From a regulatory perspective, trial listings convey intent to explore a medical device based intervention under defined inclusion criteria and monitoring requirements. The absence of efficacy results means that stakeholders should await data from formal analyses or peer reviewed publications before drawing conclusions about benefit or risk. The sponsor and coordinating sites must maintain patient safety reporting and comply with applicable trial registration obligations until the study reaches completion or is terminated.
What are implications for clinicians and patients?
For clinicians, the listing signals interest in a novel embolization based approach for chronic plantar fasciitis. Treating physicians should monitor the official clinical trial page for status changes and adhere to local regulatory guidance before considering any patient participation or referral. Practices considering enrollment or referral should ensure that patients receive appropriate consent, understand the experimental nature of the intervention, and evaluate potential risks in the context of standard care options. This information does not replace professional judgment, and outcomes may vary based on patient selection and institutional capabilities.
For patients, the listing represents an option that is being studied under supervised conditions. It is not a proven therapy or a guaranteed remedy. Individuals considering participation should discuss with their care team the potential benefits and risks, the trial protocols, and the availability of ongoing monitoring and follow up. Clinicians should direct interested patients to the official registry for updates and to the sponsor for contact information in order to obtain current enrollment details and consent requirements.
FAQ
- 1. What is Lipiodol in this context? The listing names Lipiodol as the device used in the trial and does not disclose device technical details in the public listing.
- 2. Who is sponsoring the study? Joint & Vascular Institute.
- 3. How can I learn more? See ClinicalTrials.gov for NCT07395128.
Conclusion
This is an early stage trial listing that highlights an embolization based approach for chronic plantar fasciitis. Status updates should be checked on the official ClinicalTrials.gov page, and clinicians should align any participation decisions with regulatory guidance. Stakeholders should remain cautious about drawing conclusions until more data from formal analyses become available.
Disclaimer
The information provided is for professionals and is not legal advice. It does not constitute a recommendation or endorsement of any device or procedure.
Announcement line
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07395128?term=medical+device